(firstQuint)Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years.

 Open label study to assess the safety and immunogenicity of MVA-mBN85B in healthy vaccine-naive, measles-naive and measles-experienced children.

 The study is comprised of three groups with 30 children each.

 Two groups will receive two subcutaneous (s.

c.

) immunizations 4 weeks (283 days) apart of either either 1 x 10E7 TCID50 (Group A) or 1 x 10E8 TCID50 (Group B) MVA mBN85B.

 The control group (Group C) will receive two s.

c.

 doses (0.

5 ml, 1000 TCID50) of Rouvax(R) (Sanofi-Pasteur) 24 weeks apart.

.

 Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years@highlight

Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.

